NeurologyLive Friday 5 — August 13, 2021


Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 13, 2021.

Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Peer Exchange: Shared Decision Making and Lifestyle Issues in Relapsing MS

In episode 12 of this NeurologyLive Peer Exchange series, "Optimal Management of Relapsing Multiple Sclerosis," a panel of experts including Fred D. Lublin, MD; Ravi Dukkipati, MD; Gavin Giovannoni, MD; and Lauren Gluck, MD, emphasize the importance of shared decision making in relapsing multiple sclerosis and discuss lifestyle choices that impact the disease.

2: Podcast: AHA/ASA Updates to the Stroke Care Model

Episode 44 of "Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Mitchell S.V. Elkind, MD, MS, MPhil, about the latest scientific statement from the organization about primary care's role in stroke recovery and the updated secondary prevention guidelines.

3: NeuroVoices: Jacobo Mintzer, MD, MPA, on Methylphenidate’s Impact on Alzheimer Apathy

The professor of health science at the Medical University of South Carolina discussed robust results from the phase 3 ADMET 2 study evaluating methylphenidate to treat apathy in Alzheimer disease.

4: WVE-004 Treatment for C9orf72 ALS and FTD: Merit Cudkowicz, MD

The director of the Sean M. Healey & AMG Center for ALS outlined the trial design, which will evaluate the ideal dose level and frequency of the investigational treatment for patients with C9-ALS and C9-FTD in the phase 1b/2a FOCUS-C9 trial (NCT04931862).

5: Expanding Cranial Neuralgia Research, Affiliated Surgeries: Paul G. Mathew, MD, DNBPAS, FAAN, FAHS

The assistant professor of neurology at Harvard Medical School discussed related areas of research regarding cranial neuralgias, as well as provide context on the expansion of surgical utility and identifying which patients should be eligible for them.


The 3rd Annual International Congress on the Future of Neurology® is coming up! The hybrid meeting, which will showcase the most recent advancements in neurologic disorders, is being held September 17-18, 2021, at the InterContinental New York Barclay. The target audience for this activity is physicians who treat patients with neurologic disorders. Fellows, nurses, nurse practitioners, physician assistants, and other health care professionals interested in the management of patients with neurologic disorders are also invited to participate.

The learning objectives of the program are:

  • Outline current and emerging diagnostic concepts for neurologic disorders
  • Explain clinical evidence for the management of neurologic disorders across multiple lines of care
  • Summarize the mechanism of action of therapeutic agents used to manage neurologic disorders
  • Prepare strategies for early recognition and management of treatment-related toxicities associated with neurologic therapies
  • Apply multidisciplinary care strategies for optimizing patient outcomes in the setting of neurologic disorders
  • Assess recent landmark data from clinical trials in the context of evolving treatment paradigms in neurology
Related Videos
Michael Levy, MD, PhD
Michael Kaplitt, MD, PhD
Michael Kaplitt, MD, PhD
video 4 - "Amyloid Cascade Hypothesis of Alzheimer’s Disease"
Video 3 - "Amyloid Precursor Protein and Amyloid Beta Species in Alzheimer’s Disease"
Svetlana Blitshteyn, MD, FAAN, director and founder of Dysautonomia Clinic
© 2024 MJH Life Sciences

All rights reserved.